Neal Warshoff, DO
Pulmonary Disease · Loxahatchee, FLNPI 1821198987
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 765 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 765 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Grifols USA, LLC$599
- Philips North America LLC$560
- Insmed, Inc.$478
- plus $3K from 30 others
Across 410 payments — averaging $8696.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1.5M
- Regeneron$524K
- Boehringer Ingelheim$341K
- E.r. Squibb & Sons, L.L.C.$325K
- GSK$269K
- Genentech, Inc.$200K
- plus $441K from 13 others
What the payments were for
- Food & beverage$13,99699%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 252 | $3,372 |
| AstraZeneca | 152 | $3,325 |
| Boehringer Ingelheim | 106 | $2,346 |
| Grifols USA, LLC | 42 | $599 |
| Philips North America LLC | 28 | $560 |
| Insmed, Inc. | 28 | $478 |
| United Therapeutics Corporation | 18 | $407 |
| Mylan Specialty L.p. | 20 | $405 |
| Amgen | 14 | $353 |
| Regeneron Healthcare Solutions, Inc. | 13 | $346 |
| Verona Pharma, Inc. | 14 | $274 |
| Sanofi | 10 | $272 |
| Teva Pharmaceuticals USA, Inc. | 16 | $214 |
| Genentech USA, Inc. | 8 | $177 |
| Novartis | 6 | $118 |
| Vifor Pharma, Inc. | 4 | $113 |
| Fisher & Paykel Healthcare Inc | 2 | $82 |
| Advanced Respiratory, Inc | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Baxter Healthcare | 3 | $58 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Genentech, Inc. | 1 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Merck | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Vapotherm Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Resmed Corp | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$245
- FASENRA$124
- BREZTRI AEROSPHERE$121
- BREZTRI$116
- AIRSUPRA$115
- TRELEGY ELLIPTA$112
How this compares
$14,149 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 119 | $1,527,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 515 | $450,313 |
| NucalaMepolizumab | 38 | $138,589 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 143 | $118,838 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $76,366 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $58,591 |
| Spiriva RespimatTiotropium Bromide | 83 | $58,581 |
| SymbicortBudesonide/Formoterol Fumarate | 176 | $52,566 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $50,918 |
| Arnuity ElliptaFluticasone Furoate | 100 | $32,594 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 857 | $26,618 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 101 | $16,959 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $14,851 |
| Wixela InhubFluticasone Propion/Salmeterol | 87 | $12,929 |
| BreynaBudesonide/Formoterol Fumarate | 54 | $10,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $2,346 | $1,659,892307 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,372 | $755,066893 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,325 | $171,404319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Loxahatchee
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.